A Shiraishi1,2, S Kushimoto3, Y Otomo2, H Matsui4,5, A Hagiwara6, K Murata2. 1. Emergency and Trauma Center, Kameda Medical Center, Kamogawa, Japan. 2. Trauma and Acute Critical Care Center, Tokyo Medical and Dental University Hospital of Medicine, Tokyo, Japan. 3. Division of Emergency and Critical Care Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan. 4. Clinical Research Support Office, Kameda Medical Center, Kamogawa, Japan. 5. Department of Clinical Epidemiology and Health Economics, School of Public Health, University of Tokyo, Tokyo, Japan. 6. Department of Emergency Medicine and Critical Care, National Center for Global Health and Medicine, Tokyo, Japan.
Abstract
BACKGROUND: A reduction in mortality with the early use of tranexamic acid has been demonstrated in severely injured patients who are bleeding. However, the modest treatment effect with no reduction in blood transfusion has raised concerns. The aim of the present study was to estimate the effectiveness of regular use of tranexamic acid in severely injured patients. METHODS: This multicentre observational study used retrospectively collected data from consecutive injured patients (Injury Severity Score at least 16) treated in 15 Japanese academic institutions in 2012. A propensity score-matched analysis compared patients who did or did not receive tranexamic acid administration within 3 h of injury. Study outcomes included 28-day all-cause and cause-specific mortality, and need for blood transfusion. RESULTS: Of 796 eligible subjects, 281 were treated with tranexamic acid. Propensity score matching selected a total of 500 matched subjects (250 in each group). Tranexamic acid administration was associated with lower 28-day mortality (10·0 versus 18·4 per cent; difference -8·4 (95 per cent c.i. -14·5 to -2·3) per cent) and lower 28-day mortality from primary brain injury (6·0 versus 13·2 per cent; difference -7·2 (-12·3 to -2·1) per cent). However, there was no significant difference between groups in the need for blood transfusion (33·2 versus 34·8 per cent; difference -1·6 (-9·9 to 6·7) per cent). CONCLUSION: Early tranexamic acid use was associated with reduced mortality in severely injured patients, in particular those with a primary brain injury.
BACKGROUND: A reduction in mortality with the early use of tranexamic acid has been demonstrated in severely injured patients who are bleeding. However, the modest treatment effect with no reduction in blood transfusion has raised concerns. The aim of the present study was to estimate the effectiveness of regular use of tranexamic acid in severely injured patients. METHODS: This multicentre observational study used retrospectively collected data from consecutive injured patients (Injury Severity Score at least 16) treated in 15 Japanese academic institutions in 2012. A propensity score-matched analysis compared patients who did or did not receive tranexamic acid administration within 3 h of injury. Study outcomes included 28-day all-cause and cause-specific mortality, and need for blood transfusion. RESULTS: Of 796 eligible subjects, 281 were treated with tranexamic acid. Propensity score matching selected a total of 500 matched subjects (250 in each group). Tranexamic acid administration was associated with lower 28-day mortality (10·0 versus 18·4 per cent; difference -8·4 (95 per cent c.i. -14·5 to -2·3) per cent) and lower 28-day mortality from primary brain injury (6·0 versus 13·2 per cent; difference -7·2 (-12·3 to -2·1) per cent). However, there was no significant difference between groups in the need for blood transfusion (33·2 versus 34·8 per cent; difference -1·6 (-9·9 to 6·7) per cent). CONCLUSION: Early tranexamic acid use was associated with reduced mortality in severely injured patients, in particular those with a primary brain injury.
Authors: Muhammad Khan; Faisal Jehan; Eileen M Bulger; Terence OʼKeeffe; John B Holcomb; Charles E Wade; Martin A Schreiber; Bellal Joseph Journal: J Trauma Acute Care Surg Date: 2018-11 Impact factor: 3.313
Authors: Christopher W Baugh; Michael Levine; David Cornutt; Jason W Wilson; Richard Kwun; Charles E Mahan; Charles V Pollack; Evie G Marcolini; Truman J Milling; W Frank Peacock; Rachel P Rosovsky; Fred Wu; Ravi Sarode; Alex C Spyropoulos; Todd C Villines; Timothy D Woods; John McManus; James Williams Journal: Ann Emerg Med Date: 2019-11-13 Impact factor: 5.721
Authors: Taylor N Anderson; Holly E Hinson; Elizabeth N Dewey; Elizabeth A Rick; Martin A Schreiber; Susan E Rowell Journal: J Head Trauma Rehabil Date: 2020 Sep/Oct Impact factor: 3.117
Authors: Michael M Neeki; Fanglong Dong; Jake Toy; Reza Vaezazizi; Joe Powell; David Wong; Michael Mousselli; Massoud Rabiei; Alex Jabourian; Nichole Niknafs; Michelle Burgett-Moreno; Richard Vara; Shanna Kissel; Xian Luo-Owen; Karen R O'Bosky; Daniel Ludi; Karl Sporer; Troy Pennington; Tommy Lee; Rodney Borger; Eugene Kwong Journal: West J Emerg Med Date: 2018-09-10
Authors: Shimena R Li; Francis Guyette; Joshua Brown; Mazen Zenati; Katherine M Reitz; Brian Eastridge; Raminder Nirula; Gary A Vercruysse; Terence O'Keeffe; Bellal Joseph; Matthew D Neal; Brian S Zuckerbraun; Jason L Sperry Journal: Ann Surg Date: 2021-09-01 Impact factor: 13.787